The DOI matches its Crossref record; 27 of the 28 references it cites were found in a registry or an index.
Prevalence of risk factors in men with premature coronary artery disease
Abstract
The prevalence of modifiable cardiovascular risk factors (systemic hypertension, diabetes mellitus, cigarette smoking, low-density lipoprotein [LDL] cholesterol greater than or equal to 160 mg/dl and high-density lipoprotein [HDL] cholesterol less than 35 mg/dl) was determined in 321 men less than 60 years of age (mean +/- standard deviation 50 +/- 7) with premature coronary artery disease (CAD) documented at coronary angiography. The prevalence of these risk factors was markedly different than in the Framingham Offspring Study population, used here as a comparison group. In the patients with CAD, only 3% had no risk factor (other than male sex), compared with 31% in the Framingham Offspring Study subjects. Most patients with CAD (97%) had greater than or equal to 1 additional risk factor. When the patients with CAD were divided by age groups (40 to 49 years [n = 109], 50 to 59 [n = 191]), no significant differences were observed in the prevalence of risk factors between the young and older patients. The prevalence of systemic hypertension (41 vs 19%, p less than 0.001), diabetes mellitus (12 vs 1.1%, p less than 0.001), cigarette smoking (67 vs 28%, p less than 0.001) and HDL cholesterol less than 35 mg/dl (63 vs 19%, p less than 0.001) was markedly higher in the patients with CAD than in Framingham Offspring Study subjects, whereas the prevalence of LDL cholesterol greater than or equal to 160 mg/dl was not significantly different between patients with CAD and Framingham Offspring Study subjects (26 vs 26%).(ABSTRACT TRUNCATED AT 250 WORDS)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Patients with manifest CHD frequently exhibit low HDL cholesterol (HDL-C) [2].”
From HDL cholesterol: reappraisal of its clinical relevance (2017) · cites this paper as [2]
Citations
Cites
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia
Frick, M. H., Elo, O., Haapa, K., Heinonen, O. P., Heinsalmi, P., Helo, P., Huttunen, J. K., Kaitaniemi, P., Koskinen, P., Manninen, V., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198711123172001 · Cited by 3,881
Goodman, D. S. (1988) · Archives of Internal Medicine · doi:10.1001/archinte.1988.00380010040006 · Cited by 2,458
Multiple Risk Factor Intervention Trial
Michel, D. (1982) · JAMA · doi:10.1001/jama.1982.03330120023025 · Cited by 2,211
Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin
Canner, P. L., Berge, K. G., Wenger, N. K., Stamler, J., Friedman, L., Prineas, R. J., & Friedewald, W. (1986) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(86)80293-5 · Cited by 1,824
Clofibrate and Niacin in Coronary Heart Disease
Stamler, J. (1975) · JAMA · doi:10.1001/jama.1975.03240160024021 · Cited by 1,750
Quantitative Effects of Dietary Fat on Serum Cholesterol in Man
Hegsted, D. M., McGandy, R. B., Myers, M. L., & Stare, F. J. (1965) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/17.5.281 · Cited by 1,589
High-Density Lipoprotein — The Clinical Implications of Recent Studies
Desforges, J. F., Gordon, D. J., & Rifkind, B. M. (1989) · New England Journal of Medicine · doi:10.1056/nejm198911093211907 · Cited by 1,547
The Lipid Research Clinics Coronary Primary Prevention Trial Results
(1984) · JAMA · doi:10.1001/jama.1984.03340270043026 · Cited by 1,404
Research works printed but not linked: 2
- 1988, Can Med Assoc J, 138, 1
- Warnick, 1982, Dextran sulfate-Mg2+ precipitation procedure for quantitation of high-density lipoprotein cholesterol, Clin Chem, 79, 93
Cited by
Sorted by citations
Items 101–200 of 244
Oboh, G., Bello, F. O., & Ademosun, A. O. (2014) · Journal of Food and Drug Analysis · doi:10.1016/j.jfda.2014.06.005 · Cited by 31
Nicotinic acid and other therapies for raising high-density lipoprotein
Carlson, L. A. (2006) · Current Opinion in Cardiology · doi:10.1097/01.hco.0000231404.76930.e9 · Cited by 29
Redgrave, T. G., Watts, G. F., Martins, I. J., Barrett, P. H. R., Mamo, J. C. L., Dimmitt, S. B., & Marais, A. D. (2001) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)31632-1 · Cited by 29
Hosseini, S. K., Soleimani, A., Salarifar, M., Pourhosseini, H., Nematipoor, E., Abbasi, S. H., & Abbasi, A. (2011) · Europe PMC (PubMed Central) · Cited by 28
Risk Factors for Atherosclerotic Vascular Disease
von Eckardstein, A. (2005) · Handbook of experimental pharmacology · doi:10.1007/3-540-27661-0_2 · Cited by 30
Ohta, T., Saku, K., Takata, K., Nagata, N., Maung, K. K., & Matsuda, I. (1997) · Atherosclerosis · doi:10.1016/s0021-9150(97)00163-9 · Cited by 28
Toth, P. P., Zarotsky, V., Sullivan, J. M., & Laitinen, D. (2009) · Cardiovascular Diabetology · doi:10.1186/1475-2840-8-26 · Cited by 27
Azizi, F., Rahmani, M., Raiszadeh, F., Solati, M., & Navab, M. (2002) · Coronary Artery Disease · doi:10.1097/00019501-200202000-00002 · Cited by 27
DeKroon, R. M., Robinette, J. B., Hjelmeland, A. B., Wiggins, E., Blackwell, M., Mihovilovic, M., Fujii, M., York, J. D., Hart, J. L., Kontos, C. D., et al. (2006) · Circulation Research · doi:10.1161/01.res.0000245479.03190.9f · Cited by 27
Screening for cardiovascular disease with cholesterol
SULLIVAN, D. R. (2002) · Clinica Chimica Acta · doi:10.1016/s0009-8981(01)00720-3 · Cited by 27
Statins Do Not Decrease the Risk for Wet Age-Related Macular Degeneration
Kaiserman, N., Vinker, S., & Kaiserman, I. (2009) · Current Eye Research · doi:10.1080/02713680902741670 · Cited by 26
Deramchia, K., Jacobin‐Valat, M., Vallet, A., Bazin, H., Santarelli, X., Sanchez, S., Santos, P. D. D., Franconi, J., Claverol, S., Bonetto, S., et al. (2012) · American Journal Of Pathology · doi:10.1016/j.ajpath.2012.02.013 · Cited by 26
Incremento de las HDL como arma terapéutica en la aterotrombosis
Badimón, J. J., & Ibáñez, B. (2010) · Revista Española de Cardiología · doi:10.1016/s0300-8932(10)70091-9 · Cited by 25
Muntner, P., Lee, F., & Astor, B. C. (2010) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e3181f97e4a · Cited by 25
Nadeem, N., Woodside, J. V., Kelly, S. M., Allister, R., Young, I. S., & McEneny, J. (2011) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2011.04.009 · Cited by 23
Al‐Rasadi, K., Sulaiman, K., Panduranga, P., & Al-Zakwani, I. S. (2011) · Angiology · doi:10.1177/0003319710382419 · Cited by 25
Effect of pravastatin on coronary plaque volume
Ishikawa, K., Tani, S., Watanabe, I., Matsumoto, M., Furukawa, K., Nomoto, K., Nomoto, K., Kushiro, T., Nagao, K., & Kanmatsuse, K. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00982-2 · Cited by 23
Emerging role of high-density lipoprotein in the prevention of cardiovascular disease
Brousseau, M. E. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03514-2 · Cited by 23
Mascarenhas‐Melo, F., Sereno, J., Teixeira‐Lemos, E., Marado, D., Palavra, F., Pinto, R. M. A., Rocha‐Pereira, P., Teixeira, F. J., & Reis, F. (2013) · Mediators of Inflammation · doi:10.1155/2013/612038 · Cited by 22
Modified and Dysfunctional Lipoproteins in Atherosclerosis: Effectors or Biomarkers?
Orekhov, A. N., & Sobenin, I. A. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180320121137 · Cited by 22
Singh, J. P., Kauffman, R. F., Bensch, W. R., Wang, G.-M., McClelland, P., Bean, J. S., Montrose, C., Mantlo, N. B., & Wagle, A. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.010991 · Cited by 22
Andreenko, Е. Y., Yavelov, I., Loukianov, М. М., Vernohaeva, A. N., Drapkina, O. M., & Boytsov, S. A. (2018) · Kardiologiia · doi:10.18087/cardio.2018.10.10184 · Cited by 24
Familial lipoprotein disorders and premature coronary artery disease
Schaefer, E. J. (1994) · Medical Clinics of North America · doi:10.1016/s0025-7125(16)30175-4 · Cited by 21
Self-citationImmunomodulatory effect of leaf extract of Murraya koenigii in diabetic mice
Paul, S., Bandyopadhyay, T. K., & Bhattacharyya, A. (2011) · Immunopharmacology and Immunotoxicology · doi:10.3109/08923973.2011.561354 · Cited by 20
Oyeleye, S. I., Olasehinde, T. A., Ademosun, A. O., Akinyemi, A. J., & Oboh, G. (2018) · PharmaNutrition · doi:10.1016/j.phanu.2018.100141 · Cited by 20
Schaefer, E. J., Lamon‐Fava, S., Cole, T. G., Sprecher, D. L., Cilla, D. D., Balagtas, C. C., Rowan, J. P., & Black, D. M. (1996) · Atherosclerosis · doi:10.1016/s0021-9150(96)05941-2 · Cited by 20
Self-citationLipid abnormalities in Greek patients with coronary artery disease
Elisaf, M., Siamopoulos, K. C., Tselegarides, T. J., Bairaktari, E. T., Goudevenos, J. A., Tselepis, A. D., Tsolas, O., & Sideris, D. A. (1997) · International Journal of Cardiology · doi:10.1016/s0167-5273(96)02916-6 · Cited by 19
Satoh, H., Tomita, K., Fujii, S., Kishi, R., & Tsutsui, H. (2009) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.1644 · Cited by 18
Pharmacologic Management of Isolated Low High-Density Lipoprotein Syndrome
Bermúdez, V., Cano, R., Cano, C., Bermúdez, F., Arráiz, N., Acosta, L., Finol, F., Pabón, M. R., Amell, A., Reyna, N., et al. (2008) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e318169bc0b · Cited by 17
Raziani, F., Ebrahimi, P., Engelsen, S. B., Astrup, A. V., Raben, A., & Tholstrup, T. (2018) · Nutrition & Metabolism · doi:10.1186/s12986-018-0300-0 · Cited by 18
Treating patients with low high-density lipoprotein cholesterol: choices, issues and opportunities
Watts, G. F. (2001) · Trials · doi:10.1186/cvm-2-3-118 · Cited by 17
Soyal, S. M., Sandhofer, A., Hahne, P., Oberkofler, H., Felder, T. K., Iglseder, B., Miller, K. N., Krempler, F., Patsch, J. R., Paulweber, B., et al. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.01.052 · Cited by 17
Bisgaier, C. L., Oniciu, D. C., & Srivastava, R. A. K. (2018) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000580 · Cited by 17
Niacin for Stroke Prevention: Evidence and Rationale
Keener, A. M., & Sanossian, N. (2008) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2008.00055.x · Cited by 16
Kuhlmann, J. (2007) · Springer eBooks · doi:10.1007/978-3-540-49529-1_3 · Cited by 16
Increasing High-Density Lipoprotein as a Therapeutic Target in Atherothrombotic Disease
Badimón, J. J., & Ibáñez, B. (2010) · Revista Española de Cardiología (English Edition) · doi:10.1016/s1885-5857(10)70065-7 · Cited by 17
Petto, J., Vasques, L. M. R., Pinheiro, R. L. S., Giesta, B. D. A., dos Santos, A. C. N., Neto, M. G., & Ladeia, A. M. T. (2014) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20140080 · Cited by 15
Dhuper, S., Sakowitz, S., Daniels, J., Buddhe, S., & Cohen, H. W. (2009) · Journal of Clinical Hypertension · doi:10.1111/j.1751-7176.2009.00056.x · Cited by 15
Alipour, A., van Oostrom, A. J. H. H. M., van Wijk, J. P. H., Verseijden, C., Plokker, H. W. M., Jukema, J. W., Rabelink, T. J., & Cabezas, M. C. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.03.007 · Cited by 15
Inhibitors of cholesteryl ester transfer protein – a new approach to coronary artery disease
Doggrell, S. A. (2006) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.15.2.99 · Cited by 15
New Recommendations for the Diagnosis and Treatment of Plasma Lipid Abnormalities
Schaefer, E. J. (2009) · Nutrition Reviews · doi:10.1111/j.1753-4887.1993.tb03115.x · Cited by 15
Self-citationCholesteryl Ester Transfer Protein Inhibition
Rensen, P. C. N., & Havekes, L. M. (2006) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000214979.24518.95 · Cited by 15
Efficacy of alternate day dosing of atorvastatin
Aghasadeghi, K., & Zare, D. (2007) · Open Medicine · doi:10.2478/s11536-007-0063-x · Cited by 14
Yang, R. Z., Li, L., Seidelmann, S. B., Shen, G.-Q., Sharma, S., Rao, S., Abdullah, K. G., MacKinlay, K. G., Elston, R. C., Chen, Q., et al. (2010) · Journal of Lipid Research · doi:10.1194/jlr.m004325 · Cited by 15
1 H NMR studies on serum metabonomic changes over time in a kidney-Yang deficiency syndrome model
Chen, R., Wang, J., Liao, C., Ma, N., Zhang, L., & Wang, X. (2017) · RSC Advances · doi:10.1039/c7ra04057a · Cited by 14
Bimenya, G. S., Okot, J. K., Nangosa, H., Anguma, S. A., & Byarugaba, W. (2006) · PubMed Central · doi:10.5555/afhs.2006.6.3.139 · Cited by 14
Mahungu, T. W., Nair, D. R., Smith, C. J., Egan, D., Youle, M. S., Johnson, M. A., Khoo, S., Back, D., & Owen, A. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.78 · Cited by 14
Carr, T. P., Cai, G., Lee, J., & Schneider, C. L. (2000) · Proceedings of The Society for Experimental Biology and Medicine · doi:10.1046/j.1525-1373.2000.22313.x · Cited by 14
Mamidala, E., Reddy, A. S. K., Bikshapathi, T., Satyanarayana, J., Lunavath, V., & Reddy, M. (2009) · Biology and medicine · Cited by 13
Srivastava, N., Cefalu, A. B., Averna, M. R., & Srivastava, R. A. K. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.01222 · Cited by 13
Wung, S., & Aouizerat, B. E. (2003) · Research and theory for nursing practice · doi:10.1891/088971803780956182 · Cited by 13
JTT-705: is there still future for a CETP inhibitor after torcetrapib?
Rennings, A. J. M., & Stalenhoef, A. F. H. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.10.1589 · Cited by 13
Adetunji, T. L., Adetunji, A. E., Odebunmi, C. A., van der Kooy, F., & Siebert, F. (2022) · South African Journal of Botany · doi:10.1016/j.sajb.2022.01.017 · Cited by 13
Süren‐Castillo, S., Döger, M. M., Bolkent, Ş., & Yanardağ, R. (2007) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-007-9623-2 · Cited by 12
Association between rs1049673 polymorphism in CD36 and premature coronary heart disease
Che, J., Shao, Y., & Li, G. P. (2014) · Genetics and Molecular Research · doi:10.4238/2014.september.26.8 · Cited by 12
Daylong triglyceridaemia in healthy Mediterranean and northern European subjects.
van Oostrom, A. J. H. H. M., Jt, R., Carmena, R., Ascaso, J. F., & Castro Cabezas, M. (2004) · PubMed · Cited by 11
Wang, L., Zheng, L., Luo, R., Zhao, X., Han, Z., Wang, Y., & Yang, Y. (2014) · RSC Advances · doi:10.1039/c4ra07215d · Cited by 11
Braun, L. T. (2006) · The Journal of Cardiovascular Nursing · doi:10.1097/00005082-200611001-00004 · Cited by 11
Mascarenhas‐Melo, F., Palavra, F., Marado, D., Sereno, J., Teixeira‐Lemos, E., Freitas, I., Isabel-Mendonça, M., Pinto, R. M. A., Teixeira, F. J., & Reis, F. (2013) · The Scientific World JOURNAL · doi:10.1155/2013/387849 · Cited by 11
What is the most effective strategy for managing diabetic dyslipidaemia?
Reasner, C. A. (2005) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2005.06.005 · Cited by 11
Klinische Bedeutung des HDL-Cholesterins
März, W., Kleber, M. E., Scharnagl, H., Speer, T., Zewinger, S., Ritsch, A., Parhofer, K. G., von Eckardstein, A., Landmesser, U., & Laufs, U. (2016) · Herz · doi:10.1007/s00059-016-4499-0 · Cited by 11
The beneficial effects of HDL-C on atherosclerosis: rationale and clinical results
Santos‐Gallego, C. G., Torres, F., & Badimón, J. J. (2011) · Clinical Lipidology · doi:10.2217/clp.10.90 · Cited by 10
Kaźmierski, M., Wojakowski, W., Michalewska‐Włudarczyk, A., Podolecka, E., Kotowski, M. J., Machaliński, B., & Tendera, M. (2015) · Kardiologia Polska · doi:10.5603/kp.a2014.0248 · Cited by 10
Overnight features of transcutaneous carbon dioxide measurement as predictors of metabolic status
Virkki, A., Polo, O. J., Saaresranta, T., Laapotti-Salo, A., Gyllenberg, M., & Aittokallio, T. A. (2007) · Artificial Intelligence in Medicine · doi:10.1016/j.artmed.2007.09.001 · Cited by 10
Organizing services for cardiovascular prevention
Block, R., & Pearson, T. A. (2007) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-007-0023-4 · Cited by 10
Relative survival benefits of risk factor modifications
Meyers, D. G. (1996) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)89397-6 · Cited by 10
HDL: The ‘new’ target of cardiovascular medicine
Sampietro, T., Bigazzi, F., Pino, B. D., Puntoni, M., & Bionda, A. (2005) · International Journal of Cardiology · doi:10.1016/j.ijcard.2005.04.036 · Cited by 10
Screening relatives of patients with premature coronary heart disease
Thompson, G. R. (2002) · Heart · doi:10.1136/heart.87.4.390 · Cited by 9
Treating low high-density lipoprotein cholesterol: what is the evidence?
Hage, M. P., & Azar, S. T. (2014) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018813517522 · Cited by 9
The Turkish Lipid Problem: Low Levels of High Density Lipoproteins
Mahley, R. W., Mahley, L. L., Bersot, T. P., Pépin, G. M., & Palaoğlu, K. E. (2022) · DOAJ (DOAJ: Directory of Open Access Journals) · Cited by 9
Aguirre, M., Briceño, Y., Gómez‐Pérez, R., Zerpa, Y., Camacho, N. I., & Paoli, M. (2018) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2017.10.014 · Cited by 9
Guerra, S., de Oliveira, J. J. F., Ribeiro, J. C., Teixeira-Pinto, A. M., Duarte, J. A., & Mota, J. A. P. S. (2003) · Revista Brasileira de Saúde Materno Infantil · doi:10.1590/s1519-38292003000100003 · Cited by 9
Ducobu, J., Scheen, A. J., Gaal, L. V., Velkeniers, B., & Hermans, M. P. (2008) · Acta Cardiologica · doi:10.2143/ac.63.2.2029534 · Cited by 8
Modification of High‐Density Lipoprotein Cholesterol in the Management of Cardiovascular Risk
Koeller, J. M., & Talbert, R. L. (2002) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.22.15.1266.33475 · Cited by 8
Nwaehujor, C. O., Ezeigbo, I., & Nwinyi, F. C. (2013) · Biochemistry Research International · doi:10.1155/2013/527205 · Cited by 7
Wang, Y. E., Kirschke, C. P., Woodhouse, L. R., Bonnel, E. L., Stephensen, C. B., Bennett, B. J., Newman, J. W. I., Keim, N. L., & Huang, L. (2022) · BMC Nutrition · doi:10.1186/s40795-022-00592-x · Cited by 9
Raising high-density lipoprotein cholesterol: Innovative strategies against an old adversary
Kazi, D. S., & Farmer, J. A. (2005) · Current Atherosclerosis Reports · doi:10.1007/s11883-005-0029-x · Cited by 7
Cabezas, M. C., van Heusden, G. P. H., de Bruin, T. W., van Beckhoven, J. R. C. M., Kock, L. A., WTRTZ, K. W. A., & Erkelens, D. W. (1993) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.1993.tb00751.x · Cited by 7
Correct diagnosis of chest pain by an integrated expert system
Assanelli, D., Cazzamalli, L., Stambini, M., & Poeta, M. L. (2002) · Computers in cardiology · doi:10.1109/cic.1993.378374 · Cited by 7
Lipoprotein(a) – Einfluss auf die kardiovaskuläre Manifestation
Mellwig, K., Schatton, C., Biermann, B., Kottmann, T., Horstkotte, D., & van Buuren, F. (2015) · Clinical Research in Cardiology Supplements · doi:10.1007/s11789-015-0072-2 · Cited by 6
Cho, J. Y., Jeong, M. H., Ahn, Y., Chae, S. C., Seong, I. H., Kim, Y. J., Yoon, J., Rhew, J. Y., Chae, J. K., Chae, I. H., et al. (2008) · Korean Circulation Journal · doi:10.4070/kcj.2008.38.3.161 · Cited by 6
Drugs Targeting High-Density Lipoprotein Cholesterol for Coronary Artery Disease Management
Katz, P. M., & Leiter, L. A. (2012) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2012.03.017 · Cited by 6
Aguirre, M., Briceño, Y., Gómez‐Pérez, R., Zerpa, Y., Camacho, N. I., & Paoli, M. (2017) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2017.10.010 · Cited by 6
Seccia, T. M., & Rossi, G. P. (2005) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408360500295600 · Cited by 6
Sáez, Y., Vacas, M., Santos, M. D. L., de Lafuente, J. P. S., Sagastagoitia, J. D., Molinero, E., & Iriarte, J. A. (2012) · ISRN Vascular Medicine · doi:10.5402/2012/451730 · Cited by 6
Bowen, P., & Guyton, J. R. (2000) · Current Atherosclerosis Reports · doi:10.1007/s11883-000-0095-z · Cited by 6
Jukema, J. W., Lenselink, M., de Grooth, G. J., Boekholdt, S. M., Liem, A. H., Kuivenhoven, J. A., & Kastelein, J. J. P. (2004) · PubMed Central · Cited by 5
Kılıç, İ. D., Fabris, E., Kedhi, E., Ghilencea, L.-N., Caiazzo, G., Sherif, S. A., & Mario, C. D. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00890-4 · Cited by 5
Srivastava, R. A. K., He, S., & Newton, R. S. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2010.11.004 · Cited by 6
Normocholesterolaemic dyslipidaemia: is there a role for fibrates?
Watts, G. F., Dimmitt, S. B., & Barter, P. J. (2001) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2001.tb143155.x · Cited by 5
Adepu, C., & Bandakadi, S. K. R. (2023) · Cureus · doi:10.7759/cureus.46420 · Cited by 4
Coronary Artery Disease in Young Females: Current Scenario
Kher, M., & Sathyanarayan, B. (2017) · Indian Journal of Cardiovascular Disease in Women · doi:10.1055/s-0037-1607040 · Cited by 4
Dhuper, S., Sakowitz, S., Daniels, J., Buddhe, S., & Cohen, H. W. (2009) · Journal of the CardioMetabolic Syndrome · doi:10.1111/j.1559-4572.2009.00056.x · Cited by 4
Clinical Update on the Use of Niacin for the Treatment of Dyslipidemia
Berra, K. A. (2004) · Journal of the American Academy of Nurse Practitioners · doi:10.1111/j.1745-7599.2004.tb00432.x · Cited by 4
Ghassab, R. K., Gohari, L. H., Firoozrai, M., & Yegane, M. N. (2010) · Laboratory Medicine · doi:10.1309/lmr1mwbggi3kxzei · Cited by 4
Lesná, I. K., Kovář, J., & Poledne, R. (2006) · Cor et Vasa · doi:10.33678/cor.2006.037 · Cited by 3
National Cancer Institute (2020) · Definitions · doi:10.32388/d29q7b · Cited by 3
Simultaneous Evaluation of Postchallenge Glycemia and Lipidemia in Young Women
Kuzawa, K., Morita, Y., Ichikawa, N., & Naito, M. (2021) · Journal of Food and Nutrition Sciences · doi:10.11648/j.jfns.20210906.13 · Cited by 2
Chapter 12 Recent Trends in HDL Modulating Therapies
De, D., & Khanna, I. (2007) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(07)42012-7 · Cited by 2
Metadata
- Authors
- Genest, J. J., McNamara, J. R., Salem, D. N., & Schaefer, E. J.
- Affiliations
- Tufts University (US)
- Corresponding author
- Schaefer, Ernst J.
- Venue
- The American Journal of Cardiology
- Publisher
- Elsevier BV
- Published
- 1991-06
- Volume
- 67
- Issue
- 15
- Pages
- 1185-1189
- ISSN
- 0002-9149 (ISSN-L)
- OpenAlex
- W2041225533
- Cited by
- 243
- References
- 28
- Citations by year
- 2023: 2 · 2022: 4 · 2021: 2 · 2020: 3 · 2019: 1 · 2018: 8 · 2017: 5 · 2016: 4 · 2015: 5 · 2014: 9 · 2013: 6 · 2012: 10
- FWCI
- 4.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The American Journal of Cardiology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r01hl035243-03)
- National Heart, Lung, and Blood Institute (HL 35243)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Health and Risk Factors
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- premature coronary artery disease, cardiovascular risk factors, men, systemic hypertension, diabetes mellitus, cigarette smoking, LDL cholesterol, HDL cholesterol, beta-blockers, Framingham Offspring Study, National Cholesterol Education Program guidelines, triglycerides, coronary angiography, young adults, risk factor prevalence
- MeSH terms
- Adult, Coronary Disease, Diabetes Mellitus, Humans, Hypertension, Cholesterol, HDL, Cholesterol, LDL, Male, Massachusetts, Middle Aged, Risk Factors, Smoking, Prevalence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review